久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Adagene, Sanofi ink $2.5b deal for cancer solutions

By ZHOU WENTING in Shanghai | China Daily | Updated: 2022-03-03 09:48
Share
Share - WeChat
Visitors gather at Sanofi's booth during the fourth China International Import Expo in Shanghai in November. [Provided to China Daily]

China's Adagene Inc, a Nasdaq-listed innovative biopharmaceutical company focusing on discovery and development of antibody-based novel cancer immunotherapy, announced collaboration and inked an exclusive license agreement with Sanofi for $2.5 billion on Wednesday, the company said.

According to the deal, Adagene will authorize its core technology to Sanofi and help it create new medicines. The potential transaction value to be seen through such cooperation between the domestic biopharmaceutical enterprise with its partner hit a record in its field, said industry insiders.

"Original biopharmaceutical developments from China are attracting rising international attention, and new drugs that can truly solve unmet clinical medical needs will always be the pursuit of innovation," Luo Peizhi, co-founder and CEO of Adagene, said during an exclusive interview with China Daily.

The agreement said Adagene, founded in Suzhou, Jiangsu province in 2012, will be responsible for early-stage research activities to develop versions of Sanofi candidate antibodies, using Adagene's proprietary technology. Sanofi will be responsible for later-stage research and clinical, product development and commercialization activities.

"We look forward to working with Adagene to design antibodies that can help us bring transformative new medicines to people living with cancer," said Valeria Fantin, global head of oncology research at Sanofi.

"Adagene's antibody platform is expected to help us precisely target established, but poorly addressed oncology mechanisms with best-in-class medicines," she said.

Luo said the proprietary technology is a precision antibody masking platform designed to enable the antibody to bind to its target specifically only after conditional activation of the antibody in target tissues.

By engineering and developing therapeutic antibody candidates to selectively activate in the tumor microenvironment, the platform is designed to improve safety and tolerability of antibody therapeutics while maintaining clinical activity.

"This core technology from us has been proven through extensive preclinical and clinical data. So far, a very limited number of companies can develop and apply such technology with clinically validated efficacy," Luo said.

Raymond Tam, chief financial officer of Adagene, said the company's gains from the authorization are fairly competitive in terms of both upfront fees and total potential milestone payments. The company will also get tiered royalties on future global net sales, he said.

Industry observers said that China is expected to enter the world's first echelon in new drug research and development within the next decade, and multinational pharmaceutical giants are deepening collaboration with local players in recent years.

The United States Food and Drug Administration on Monday approved CAR-T, a tumor immunotherapy, to treat adults with multiple myeloma. The medicine was a potentially best-in-class innovative tumor drug developed by Nanjing-based Legend Biotech. Later, Janssen Pharmaceutical joined in its development.

Last month, US-based Eli Lilly, which reached deals with more than 10 Chinese pharmaceutical enterprises in clinical development projects among others over the past decade, established its China innovation incubation platform in Shanghai's Zhangjiang High-Tech Park to join hands with more partners to create original medications from local sources.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 狠狠色婷婷丁香综合久久韩国 | 韩日精品| 免费人成激情视频在线观看冫 | 波少野结衣在线播放 | 毛片在线免费播放 | 午夜两性视频 | 久草色视频| 国产在线观看一区二区三区四区 | 亚洲成aⅴ人片在线观 | 免费人成在线观看视频不卡 | 69福利网 | 欧美xxxx在线视频 | 国产www| 俄罗斯一级成人毛片 | 看免费人成va视频全 | 久久精品国产精品亚洲综合 | 欧美成人精品大片免费流量 | 亚洲清纯自偷自拍另类专区 | 在线观看精品视频一区二区三区 | 日韩经典在线观看 | 国产在线播放不卡 | 毛片a级三毛片免费播放 | jyzzjyzz国产免费观看 | 国产a高清| 亚洲综合精品 | 亚洲天堂影院在线观看 | 欧美亚洲国产精品久久高清 | 欧美亚洲国产成人综合在线 | 中文乱码字幕午夜无线观看 | 26uuu欧美日韩国产 | 久久久免费网站 | 色日韩在线 | 性欧美videofree另类17 | 国自产精品手机在线视频香蕉 | 97视频久久 | 全部免费的毛片在线看美国 | 99在线小视频 | 日韩欧美在线视频观看 | 香港全黄一级毛片在线播放 | 久久久亚洲精品国产 | 婷婷三级|